I need to extract the substantive financial disclosure content from this 10-Q filing to check if it meets the 150-word threshold, then produce the article. The filing covers the quarterly period ended September 30, 2026, for Kymera Therapeutics, Inc., listed on The Nasdaq Global Market under symbol KYMR. The filing includes share count (85,371,397 as of October 23, 2026), risk factor summaries, and forward-looking statement disclosures. The substantive content (share count, company stage disclosures, risk summaries, program mentions including IRAK4, CDK2, STAT6, IRF5) exceeds 150 words.

Kymera Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on October 29, 2026, covering the fiscal quarter ended September 30, 2026, disclosing its clinical-stage status, operating losses, and key program updates.

Key Highlights

  • Share count: As of October 23, 2026, the company had 85,371,397 shares of common stock, $0.0001 par value per share, outstanding.
  • Clinical-stage company: The company disclosed it is a clinical-stage company and has incurred significant operating losses since inception, anticipating continued losses for the foreseeable future.
  • Capital needs: According to the filing, the company "will need to raise substantial additional funding" or may be forced to delay, scale back, or discontinue development programs.
  • Active programs: The filing references development efforts under collaborations for IRAK4 and CDK2 programs, as well as clinical studies for STAT6 and IRF5 programs.
  • Filer classification: The registrant is classified as a large accelerated filer, not a smaller reporting company or emerging growth company.
  • Filing compliance: The company confirmed it has filed all required reports during the preceding 12 months and submitted all required Interactive Data Files electronically.

Kymera Therapeutics Reports Q3 2026 Status Across IRAK4, CDK2, STAT6, and IRF5 Programs

Kymera Therapeutics, Inc. (NASDAQ:KYMR), headquartered at 500 North Beacon Street, 4th Floor, Watertown, Massachusetts 02472, filed its Form 10-Q for the quarterly period ended September 30, 2026. The company disclosed that it is a clinical-stage company, a designation it acknowledged "may make it difficult for our stockholders to evaluate the success of our business to date and to assess our future viability." As of October 23, 2026, there were 85,371,397 shares of common stock outstanding.

According to the filing, Kymera "has incurred significant operating losses since our inception" and anticipates continued losses going forward. The company stated it will need to raise substantial additional funding, and that failure to do so "would be forced to delay, scale back or discontinue some of our product candidate development programs or future commercialization efforts." The filing notes the company's approach to discovery and development is "novel and unproven," making it difficult to predict development timelines, costs, and likelihood of success.

The quarterly report references the company's pipeline, including collaboration programs for IRAK4 and CDK2 and clinical studies for STAT6 and IRF5 programs. The filing also lists a range of risk factors relevant to the business, including reliance on third parties for clinical trials, intellectual property risks, and potential disruptions from global economic and geopolitical conditions. The filing contains forward-looking statements made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which the company notes are "not guarantees of future results or performance and involve substantial risks and uncertainties."

What Was Disclosed

Kymera Therapeutics filed a quarterly report for the period ended September 30, 2026, disclosing its clinical-stage status, 85,371,397 shares outstanding as of October 23, 2026, anticipated continued operating losses, capital needs, and active pipeline programs including IRAK4, CDK2, STAT6, and IRF5.